AuroBlog - Aurous Healthcare Clinical Trials blog
APRIL 21, 2024
Not getting enough sleep is a common affliction in the modern age. If you don’t always get as many hours of shut-eye as you’d like, perhaps you were concerned by news of a recent study that found people who sleep less than six hours a night are at higher risk of type 2 diabetes.
Pharma Mirror
APRIL 21, 2024
An article by Aloiz Kara Aging represents a risk factor for many health problems and diseases, which means that as we grow older, there is a high probability that our health will change negatively. While some of those health issues could be attributed to a hectic lifestyle, the same way of living could keep you from getting the necessary prescribed medicine.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
BioSpace
APRIL 21, 2024
A one-time treatment for Parkinson’s disease could be a ‘market changer,’ experts told BioSpace, adding that cell therapies could limit the adverse effects seen with current drugs.
Pharma Mirror
APRIL 21, 2024
Periodontal Disease (PD) is a severe, progressive gum infection that targets the gums, inflaming and damaging the soft tissue and supporting bone around the teeth. PD is caused by pathogenic microflora in the biofilm that forms below the gum line adjacent to the teeth. The infection begins as gingivitis, which leads to periodontitis, causing the gums to recede and eventually destroy the bone supporting the teeth causing the teeth to loosen.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
BioSpace
APRIL 21, 2024
From gene-corrected cell therapies to a new CAR-T, the cell and gene therapy space looks to expand its reach into the market.
Pharma Mirror
APRIL 21, 2024
With the rapid development of biotechnology and molecular medicine, the introduction of mRNA as a vaccine or therapeutic agent enables the production of almost any desired functional protein/peptide within the human body. This represents an increasingly promising field of precision medicine, holding significant prospects for preventing and treating numerous challenging or genetic diseases.
Clinical Research Informer brings together the best content for clinical researchers from the widest variety of industry thought leaders.
Pharma Mirror
APRIL 21, 2024
The healthcare industry is actively digitalizing and employing modern tools to enrich the grade of service. Clinics incorporate virtual waiting rooms, among other software, to boost patient care and improve staff workflow in traditional medical establishments. In this guide, we’ll investigate the advantages of virtual hospital waiting rooms and how they are revolutionizing healthcare.
JAMA Internal Medicine
APRIL 21, 2024
This cohort study using a target trial emulation approach assesses whether initiating antihypertensive medication is associated with increased fracture risk among older long-term Veterans Health Administration nursing home residents.
Pharma Mirror
APRIL 21, 2024
The healthcare landscape is rapidly transforming, fueled by the convergence of technology and medicine. Among the myriad of innovations, the Internet of Things (IoT) stands out as a beacon of hope, promising to revolutionize patient care, streamline operations, and enhance medical outcomes. As we delve into the IoT in Healthcare Market Outlook for 2031, the data paints a vivid picture of an industry poised for unprecedented growth and innovation.
BioSpace
APRIL 21, 2024
The FDA will close out April with five target action dates around indications that include pediatric seizures and a neurological cancer in children.
Drug Patent Watch
APRIL 21, 2024
Annual Drug Patent Expirations for SOOLANTRA Soolantra is a drug marketed by Galderma Labs Lp and is included in one NDA. It is available from three suppliers.
BioSpace
APRIL 21, 2024
While Madrigal Pharmaceuticals secured the first FDA drug approval for metabolic dysfunction–associated steatohepatitis, Akero Therapeutics is developing what may serve as a viable alternative treatment for precirrhotic disease.
pharmaphorum
APRIL 21, 2024
Generics of Astellas’ Myrbetriq for urinary incontinence are looming in the US after a court recommended against an injunction on copycats from Zydus and Lupin
BioSpace
APRIL 21, 2024
Drugmakers, including the genetic testing company 23andMe, are using novel approaches to stimulate NK cells’ intrinsic ability to recognize and kill tumor cells.
Advertisement
White paper that delves into the complex topic of Decentralized Clinical Trials and how to master them within the confines of FDA Regulations
Drug Patent Watch
APRIL 21, 2024
This chart shows the pharmaceutical companies with the most syrup dosed drugs. For a different perspective, see the most popular dosage types.
BioSpace
APRIL 21, 2024
Following an investigation regarding antitrust practices against Pharmacosmos’ Monofer, CSL Vifor has proposed a sweeping multi-channel communication campaign designed to reverse allegedly misleading messages about its rival.
BioSpace
APRIL 21, 2024
Ipsen is looking to deepen its expertise in movement disorders in a research collaboration with Skyhawk Therapeutics to develop small molecule drugs for RNA targets in neurological diseases.
Drug Patent Watch
APRIL 21, 2024
Annual Drug Patent Expirations for MEGACE+ES Megace Es is a drug marketed by Endo Pharms Inc and is included in one NDA.
BioSpace
APRIL 21, 2024
As AbbVie and NeuroDerm race toward potential U.S. approvals later this year, the companies presented strong data at last week’s American Academy of Neurology 2024 annual meeting for their respective continuous subcutaneous levodopa infusions.
FDA Law Blog
APRIL 21, 2024
By Kurt R. Karst — If you’ve been following this blog since the early days, then you know we fervently followed the more-than-decade-long soap opera that was The Medicines Company’s efforts to obtain a Patent Term Extension (“PTE”) from the U.S. Patent and Trademark Office (“PTO”) for U.S. Patent No. 5,196,404 covering ANGIOMAX (bivalirudin) after the company’s patent counsel untimely filed for a PTE 62 days after the ANGIOMAX NDA 020873 approval at 5:18 PM on Friday, December 15, 2000 (see our
BioSpace
APRIL 21, 2024
Boehringer Ingelheim is paying $35 million in upfront and near-term fees to work with Ochre Bio to identify and validate regenerative targets for metabolic dysfunction-associated steatohepatitis and other chronic liver diseases.
Advertisement
This new white paper defines and details the impact of Decentralized Clinical Trials on the Pharmaceutical industry and how the impact can be measured along with steps companies can take to ensure adoption.
JAMA Internal Medicine
APRIL 21, 2024
In this study, Dave et al harness national Veterans Health Administration (VHA) clinical data to examine the association between initiation of a new antihypertensive agent with the incidence of fall-related fractures in residents at VHA nursing homes, or community living centers. In this carefully designed study, residents who received a new antihypertensive agent had more than 2-fold greater risk of fractures compared with those who did not (adjusted hazard ratio [aHR], 2.42 [95% CI, 1.43-4.08]
BioSpace
APRIL 21, 2024
Bolstered by its portfolio of “revolutionary” therapies, AbbVie remains the top pharma company in the immunology space, according to a new survey of doctors by ZoomRx.
BioSpace
APRIL 21, 2024
Bristol Myers Squibb will be using Cellares’ Cell Shuttles, an automated production system capable of producing multiple cell therapies simultaneously, to potentially improve turnaround time to support the pharma’s CAR T cell therapies.
Expert insights. Personalized for you.
132 
Let's personalize your content